Drug Profile
Research programme: serratamolide analogues - CRT/University of Barcelona
Alternative Names: AT 514Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Barcelona
- Developer Cancer Research Technology; University of Barcelona
- Class
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Spain
- 10 Mar 2006 Preclinical trials in Cancer in Spain (unspecified route)